Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma.

Trial Profile

Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Otlertuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Emergent Product Development Seattle
  • Most Recent Events

    • 23 Mar 2012 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Actual patient number is 96 according to ClinicalTrials.gov.
    • 23 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top